Abstract Archives of the RSNA, 2010
SSA21-03
Sonoactived Doxorubicin Loaded Nanoliposomes
Scientific Formal (Paper) Presentations
Presented on November 28, 2010
Presented as part of SSA21: Physics (Ultrasound)
Saujanya Laxmirajam Gosangari PhD, Abstract Co-Author: Researcher, Banner Pharmaceutical
Kenneth Lloyd Watkin MS, PhD, Presenter: Stockholder, Ultra-Imaging LLC
Stockholder, SonoActive Inc
This research demonstrates that medical diagnostic ultrasound energy levels have the capability to enhance release from specially formulated nanoliposomes, wherein the release is a function of the lipid composition, irradiation times and power intensity level.
Liposomes as drug delivery carriers have been pursued for several decades. Anticancer drugs have been formulated in lipid vesicles to achieve high encapsulation coupled with resistance to leakage and drug loss while in circulation. Surface chemistry can be employed to modify the liposome surface to carry specialized molecules and proteins, which further enhances the functionality of these liposomes.
Liposomal formulations of anthracyclines have been used extensively for cancer treatment to facilitate increased drug accumulation and uptake at the tumor site. Once the drug is incorporated into the liposome and has reached the tumor site, the biggest challenge is the release of the contents.
In this research we report on a modified medical diagnostic ultrasound system that has been utilized with specially formulated nanoliposomes to demonstrated the effectiveness of sonoactive delivery of doxorubicin nanoliposomes.
A specially modified 7.5 MHz diagnostic ultrasound system (Aloka systems) was used for the release experiments. The nanoliposomes were irradiated for four different pulse repetition times; 100, 250, 500, and 1000 microseconds. The power intensity levels and the time of irradiation were also varied The ultrasound sensitive nanoliposomes released increasing amounts of drug in response to increasing irradiation times and energy levels while the drug release was not significant when the non-ultrasound sensitive nanoliposomes were exposed to ultrasound energy levels. In vitro studies to test the cytotoxicity of the formulations demonstrateded that doxorubicin loaded nanoliposomes significantly inhibited cell survival of oral cancer cells when compared to the non-ultrasound sensitive nanoliposomes.
This research highlights the need to control not only the ultrasound parameters for sonoactivation but also the need for special formulations of lipid nanoparticles for ultrsound mediated delivery.
Gosangari, S,
Watkin, K,
Sonoactived Doxorubicin Loaded Nanoliposomes. Radiological Society of North America 2010 Scientific Assembly and Annual Meeting, November 28 - December 3, 2010 ,Chicago IL.
http://archive.rsna.org/2010/9013031.html